GLP-1s and Constipation: Managing the Other GI Effect

Semaglutide and tirzepatide get talked about mostly for nausea, but constipation is at least as common and gets far less attention. It’s rarely dramatic enough to make someone stop treatment, but it’s persistent, uncomfortable, and often mismanaged simply because people don’t expect it or don’t know what to do about it.

Why GLP-1 drugs cause constipation

GLP-1 receptor agonists slow gastric emptying — that’s part of how they reduce appetite and blunt post-meal glucose spikes. The same mechanism that keeps food in the stomach longer also slows transit further down the GI tract. Slower motility means stool moves through the colon more slowly, more water gets reabsorbed along the way, and stool becomes harder and less frequent.

There’s a second, less obvious contributor: people on these drugs simply eat and drink less. Reduced fiber intake, reduced overall food volume, and — easy to overlook — reduced fluid intake all push in the same direction. Someone who was previously eating regular meals with reasonable roughage and now eats a fraction of that, without deliberately compensating, is set up for constipation independent of the drug’s direct effect on gut motility.

How common is it, really

In the pivotal semaglutide trials, including the STEP program reported by Wilding and colleagues in NEJM (2021), constipation was among the more frequently reported gastrointestinal adverse events, trailing nausea, vomiting, and diarrhea in overall frequency but still affecting a meaningful minority of participants — commonly cited in the range of roughly one in ten to one in five, depending on the trial, the dose, and how symptoms were defined and tolerated. Tirzepatide trials report similar patterns. These are trial populations on structured titration schedules, so real-world rates during rapid dose escalation, or in people not otherwise counseled on diet, may run higher. Prescribing information for both semaglutide and tirzepatide lists constipation as a common adverse reaction, and it tends to persist for as long as someone stays on therapy rather than resolving after the first few weeks the way nausea often does.

Constipation on a GLP-1 is usually a manageable side effect of slower gut transit and lower intake — not a sign something has gone wrong — but it deserves the same proactive attention as nausea, not an afterthought.

What actually helps

None of this is exotic. The basics that help ordinary constipation help here too, and they matter more because the underlying drive — slowed motility plus reduced intake — doesn’t go away on its own.

• Fluids. Reduced appetite often comes with reduced thirst cues too. Deliberately maintaining fluid intake, rather than waiting to feel thirsty, is one of the more overlooked fixes.
• Fiber. Both soluble and insoluble fiber help, but ramping up quickly on someone already eating less can cause bloating. A gradual increase, alongside adequate fluid, tends to be better tolerated than a sudden jump.
• Movement. Regular physical activity, even light walking, supports gut motility. This is one of the few places where general health advice and GI symptom management overlap directly.
• Timing meals and doses. Some people find symptoms track with dose escalation steps; slowing the titration schedule, with a clinician’s input, sometimes helps GI side effects broadly, including constipation.
• Osmotic laxatives. When diet and lifestyle steps aren’t enough, an osmotic laxative such as polyethylene glycol is a common next step and is generally considered reasonable for this kind of drug-associated constipation, but that’s a decision to make with a clinician rather than a default add-on, especially for anything used regularly.
• Stimulant laxatives, as a shorter-term measure. These have a role for occasional relief but aren’t typically the first-line choice for ongoing motility-related constipation without medical guidance.

What doesn’t make sense is ignoring it and hoping it resolves the way nausea often does in the first weeks. Motility-driven constipation tends to persist for as long as the mechanism causing it — slowed gastric and intestinal transit — remains in effect, which is to say, for as long as someone is on the drug.

When it’s not just constipation

There’s a meaningful distinction between routine constipation and a more serious motility problem. Case reports and post-marketing surveillance have raised concerns about rare but serious events including ileus (a temporary halt in intestinal movement) and, less commonly, bowel obstruction associated with GLP-1 receptor agonists. These are uncommon, but the warning signs are worth knowing rather than filing away: severe or worsening abdominal pain, distension, persistent vomiting, or an inability to pass gas or stool at all. That combination is different from ordinary constipation and is a reason to contact a clinician promptly rather than wait it out with more fiber and water.

The takeaway

Constipation on a GLP-1 is common, largely explainable by slower gut transit and lower food and fluid intake, and usually manageable with the same fiber-fluids-movement approach that helps constipation generally, stepping up to an osmotic laxative if needed. It’s worth raising proactively with a prescriber rather than waiting for it to become disruptive — and it’s worth knowing the difference between “uncomfortable but ordinary” and the rarer warning signs that point toward something like ileus, which needs prompt medical evaluation rather than home management.

Sources

• Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021
• Wegovy (semaglutide) Prescribing Information — DailyMed, National Library of Medicine
• Gastrointestinal Adverse Effects of GLP-1 Receptor Agonists — StatPearls, NCBI Bookshelf
• Constipation — NIDDK, National Institutes of Health